Save to Existing Project
Save to a New Project
Yeda R&D Co. Ltd
Abstract ID: 1667
Type 1 Diabetes Mellitus (T1D) is caused by the autoimmune destruction of pancreatic insulin-producing beta cells. It is an incurable disease and cannot be prevented. While the existing...
Type 1 Diabetes Mellitus (T1D) is caused by the autoimmune destruction of pancreatic insulin-producing beta cells. It is an incurable disease and cannot be prevented. While the existing treatments can arrest or inhibit the destruction of beta cells, currently no therapy exists that is effective in the millions of longstanding T1D patients, who have no residual beta cells.
There is a need for an innovative treatment for beta cell regeneration in longstanding diabetics.
The proposed technology demonstrates that DiaPep277 is capable of inducing beta cell regeneration after the initial supply of beta cells is gone.
DiaPep277, a p277-derived synthetic peptide administered in a digestible lipid vehicle such as Lipofundin, was shown to be effective in treatment of newly-diagnosed T1D patients by modulating and arresting the autoimmune destruction of residual beta cells. It has successfully completed a phase III clinical trial. However, DiaPep277 was never suspected to be effective in treating patients with advanced T1D who have no residual beta cells. Surprisingly, it was found in a study conducted by Prof. Cohen and his team that under a different dosage regimen, DiaPep277 is capable of inducing beta cell regeneration in NOD mice with advanced T1D. Specifically, the treated mice show increased survival, decreased blood glucose levels, and higher levels of C-peptide, a biomarker for endogenous insulin production.
A novel method is presented here for treating established diabetics. It is based on the surprising discovery that DiaPep277, already proven effective in arresting the autoimmune destruction of residual beta cells, is capable of inducing beta cell regeneration in NOD mice with advanced T1D, thus rendering DiaPep277 suitable for treating longstanding T1D patients.
Please enquire quoting reference no. 1667 regarding licensing or codevelopment partnerships.
Last Updated May 2015